gemfibrozil has been researched along with Hyperlipoproteinemia Type IV in 26 studies
Hyperlipoproteinemia Type IV: A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of gemfibrozil and colestipol with gemfibrozil and lovastatin in patients with familial combined hyperlipidemia." | 5.06 | Combination drug therapy for familial combined hyperlipidemia. ( Bilheimer, DW; East, C; Grundy, SM, 1988) |
| "After study at entry, in 56 women (median age, 52 years), 36 with familial hypertriglyceridemia, to lower triglycerides, estrogens and SERMs (hormone treatment, HT) were stopped; a very low fat diet (<15% of calories), gemfibrozil (1." | 3.72 | An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. ( Glueck, CJ; Goldenberg, NM; Wang, P, 2003) |
| "In the control group (n=18), a hypolipidemiant diet alone was indicated." | 2.71 | Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. ( Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R, 2003) |
| "Gemfibrozil (G) is a widely used and highly effective fibric acid derivative." | 2.67 | Activity profile of gemfibrozil on the major plasma lipoprotein parameters. ( Bertoli, M; Calabresi, L; Chiesa, G; Franceschini, G; Gianfranceschi, G; Maderna, P; Sirtori, CR; Vaccarino, V, 1992) |
| "Treatment with gemfibrozil resulted in a reduction in serum triglyceride concentrations at all time points for at least 5 h after the meal (P less than 0." | 2.67 | Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. ( Arrol, S; Bhatnagar, D; Durrington, PN; Mackness, MI; Prais, H; Winocour, PH, 1992) |
| "Gemfibrozil was given at the dose of 600 mg twice daily to 16 type IIa, 13 type IIb and 11 type IV hyperlipoproteinaemic patients for four months." | 2.66 | Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil. ( Branchi, A; Fasoli, A; Orlandi, S; Pini, C; Scandiani, L; Sommariva, D, 1988) |
| "Gemfibrozil is a potent lipid regulating drug whose major effects are to increase plasma high density lipoproteins (HDL) and to decrease plasma triglycerides (TG) in a wide variety of primary and secondary dyslipoproteinemias." | 1.27 | Mechanism of action of gemfibrozil on lipoprotein metabolism. ( Gartside, PS; Hynd, BA; Kashyap, ML; Saku, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (53.85) | 18.7374 |
| 1990's | 9 (34.62) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández, C | 1 |
| Lecube, A | 1 |
| Barberá, G | 1 |
| Chacón, P | 1 |
| Lima, J | 1 |
| Simó, R | 1 |
| Goldenberg, NM | 1 |
| Wang, P | 1 |
| Glueck, CJ | 1 |
| Nash, DT | 1 |
| Dahlén, G | 1 |
| Gillnäs, T | 1 |
| Børresen, AL | 1 |
| Berg, K | 1 |
| Ericson, C | 1 |
| Borowitz, D | 1 |
| Scheig, R | 1 |
| Polakowska, M | 1 |
| Broda, G | 1 |
| Rywik, S | 1 |
| Piotrowski, W | 1 |
| Bednarska, M | 1 |
| Kuźmińska, A | 1 |
| Pytlak, A | 1 |
| Chotkowska, E | 1 |
| Tavella, M | 1 |
| Corder, CN | 2 |
| McConathy, W | 1 |
| Otto, C | 1 |
| Pschierer, V | 1 |
| Soennichsen, AC | 1 |
| Schwandt, P | 1 |
| Richter, WO | 1 |
| Bergemann, R | 1 |
| Brandt, A | 1 |
| Siegrist, W | 1 |
| Pedreño, J | 1 |
| Hurt-Camejo, E | 1 |
| Wiklund, O | 1 |
| Badimón, L | 1 |
| Masana, L | 1 |
| Sirtori, CR | 1 |
| Franceschini, G | 1 |
| Gianfranceschi, G | 1 |
| Vaccarino, V | 1 |
| Chiesa, G | 1 |
| Maderna, P | 1 |
| Bertoli, M | 1 |
| Calabresi, L | 1 |
| Bhatnagar, D | 1 |
| Durrington, PN | 1 |
| Mackness, MI | 1 |
| Arrol, S | 1 |
| Winocour, PH | 1 |
| Prais, H | 1 |
| Monova, D | 1 |
| Petrova, V | 1 |
| Belovezhdov, N | 1 |
| Kashyap, ML | 2 |
| Saku, K | 2 |
| Kloer, HU | 1 |
| Price, MD | 1 |
| Alvarez-Sabin, J | 1 |
| Codina, A | 1 |
| Rodríguez, C | 1 |
| Laporte, JR | 1 |
| Sommariva, D | 1 |
| Branchi, A | 1 |
| Pini, C | 1 |
| Scandiani, L | 1 |
| Orlandi, S | 1 |
| Fasoli, A | 1 |
| East, C | 1 |
| Bilheimer, DW | 1 |
| Grundy, SM | 2 |
| Sznajd, J | 2 |
| Malczewska-Malec, M | 2 |
| Idzior-Waluś, B | 2 |
| Jamska, B | 1 |
| Nowacki, G | 2 |
| Iwanejko, J | 1 |
| Weintraub, MS | 1 |
| Eisenberg, S | 1 |
| Breslow, JL | 1 |
| Gotto, AM | 1 |
| Jones, PH | 1 |
| Scott, LW | 1 |
| Vega, GL | 1 |
| Schaefer, EJ | 1 |
| Levy, RI | 1 |
| Gartside, PS | 1 |
| Hynd, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for gemfibrozil and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylom | 1985 |
11 trials available for gemfibrozil and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hy | 2003 |
Effect of gemfibrozil on serum lipid levels.
Topics: Cholesterol; Clinical Trials as Topic; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipop | 1980 |
Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles.
Topics: Adult; Apolipoproteins E; Blood Platelets; Double-Blind Method; Gemfibrozil; Humans; Hyperlipoprotei | 2000 |
Activity profile of gemfibrozil on the major plasma lipoprotein parameters.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Ge | 1992 |
Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins.
Topics: Adult; Cholesterol Esters; Double-Blind Method; Gemfibrozil; Humans; Hyperlipoproteinemia Type IV; L | 1992 |
CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
Topics: Apolipoproteins; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Humans; Hyperli | 1989 |
Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil.
Topics: Adolescent; Adult; Aged; Apolipoproteins A; Apolipoproteins B; Clinical Trials as Topic; Drug Admini | 1988 |
Combination drug therapy for familial combined hyperlipidemia.
Topics: Adult; Cholelithiasis; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipi | 1988 |
[Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Female; Gemfibrozil; Humans | 1987 |
[Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
Topics: Apolipoproteins; Cholesterol; Clinical Trials as Topic; Gemfibrozil; Humans; Hyperlipoproteinemia Ty | 1987 |
Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hyperlipide | 1985 |
12 other studies available for gemfibrozil and Hyperlipoproteinemia Type IV
| Article | Year |
|---|---|
An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Interactions; Estrogen Replacement Therapy; Fatty Acids | 2003 |
Gemfibrozil--a new lipid lowering agent.
Topics: Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Humans; | 1980 |
Recurrent abdominal pain in a patient with cystic fibrosis and type IV hyperlipidemia.
Topics: Abdominal Pain; Adolescent; Cystic Fibrosis; Gemfibrozil; Humans; Hyperlipoproteinemia Type IV; Male | 1995 |
[Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
Topics: Adolescent; Adult; Aged; Cholesterol; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hyperlipoprote | 1994 |
Effect of gemfibrozil on fatty acids in lipid fractions of plasma from patients with hypertriglyceridemia.
Topics: Fatty Acids; Fatty Acids, Unsaturated; Gemfibrozil; Humans; Hyperlipoproteinemia Type IV; Hyperlipop | 1993 |
Postprandial hemorrheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia.
Topics: Adult; Apolipoproteins B; Fasting; Female; Gemfibrozil; Hematocrit; Humans; Hyperlipoproteinemia Typ | 1997 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperl | 1993 |
[Gemfibrozil in the treatment of hyperlipoproteinemias].
Topics: Adult; Aged; Cholesterol; Drug Evaluation; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II | 1991 |
HDL metabolism in HDL deficiency associated with familial hypertriglyceridemia: effect of treatment with gemfibrozil.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins A; Drug Therapy, Combination; Gemfibrozil; | 1991 |
Gemfibrozil-induced headache.
Topics: Gemfibrozil; Headache; Humans; Hyperlipoproteinemia Type IV; Male; Middle Aged; Time Factors | 1988 |
Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
Topics: Cholestyramine Resin; Chylomicrons; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia | 1987 |
Mechanism of action of gemfibrozil on lipoprotein metabolism.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins | 1985 |